AQR Capital Management
AVDL

AQR Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

AQR Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,963
Closed -$430K – 3748
2025
Q4 		$430K Sell
19,963
-48,119
-71% -$934K ﹤0.01% 2992
2025
Q3 		$1.04M Buy
68,082
+32,461
+91% +$422K ﹤0.01% 2413
2025
Q2 		$315K Buy
+35,621
New +$313K ﹤0.01% 2848

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

AQR Capital Management's AVDL Position: Q1 2026 in Review

AQR Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 19,963 shares — an estimated $430K sold.

AQR Capital Management first reported a position in AVDL in Q2 2025 and held it in 3 quarters. The position peaked at $1.04M in Q3 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • AQR Capital Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • AQR Capital Management sold 19,963 Avadel Pharmaceuticals shares in Q1 2026, an estimated $430K.
  • AQR Capital Management first reported a position in Avadel Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • AQR Capital Management's Avadel Pharmaceuticals position peaked at $1.04M in Q3 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.